Finance

Lists
DMRA:NASDAQ
Damora Therapeutics Inc
$30.31
-6.57%
(-2.13) 1D
$30.31
0.00% (0.00)
After hours
Closed: Aug 20, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DMRA...
Open
$31.84
High
$32.07
Low
$30.12
Mkt. cap
1.87B
Avg. vol.
418.19K
Volume
0.00
52-wk high
$34.89
52-wk low
$16.50
EPS
-$139.34
Beta
1.47
Shares outstanding
61.74M
No. of employees
7
Open
$31.84
High
$32.07
Low
$30.12
Mkt. cap
1.87B
Avg. vol.
418.19K
Volume
0.00
52-wk high
$34.89
52-wk low
$16.50
EPS
-$139.34
Beta
1.47
Shares outstanding
61.74M
No. of employees
7
News stories
From web sources and news partners
About Damora Therapeutics Inc
CEO-
Employees7
Founded2011
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitedamoratx.com
Analyst ratings
Based on 7 analysts giving stock ratings to DMRA in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for DMRA in the last 3 months.
Highest
Current $30.31
$50.00 (+64.96%)
Average
$43.33 (+42.96%)
Lowest
$40.00 (+31.97%)
Analyst
Recommendation
Action
Price target
Projected
Date
Akash Tewari
Jefferies
Buy
Maintained
$50.00
+65%
08/11/2026
David Nierengarten
Wedbush
Buy
Maintained
$40.00
+32%
08/11/2026
Brian Abrahams
RBC Capital
Buy
Maintained
$40.00
+32%
08/10/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$45.00
+48.5%
08/11/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$45.00
+48.5%
08/11/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
08/10/2026
Bradley Canino
Guggenheim
Buy
Maintained
$40.00
+32%
06/15/2026
Andrew Berens
Leerink Partners
Buy
Maintained
$51.00
+68.3%
05/15/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Initiated
$46.00
+51.8%
03/25/2026
Michael Yee
UBS
Buy
Initiated
$45.00
+48.5%
02/17/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
1.42M
23.32M
23.78M
25.54M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.74M
4.07M
7.03M
9.45M
Operating expense
3.16M
27.39M
30.81M
34.99M
Total operating expenses
3.16M
27.39M
30.81M
34.99M
Operating income
-3.16M
-27.39M
-30.81M
-34.99M
Other non operating income
-
-
-
-
EBT including unusual items
-3.13M
-200.69M
-27.74M
-30.92M
EBT excluding unusual items
-3.13M
-26.38M
-27.74M
-30.92M
Income tax expense
-
44.00K
42.00K
255.00K
Effective tax rate
-
-0.02%
-0.15%
-0.82%
Other operating expenses
-
-
-
-
Net income
-3.13M
-200.74M
-27.78M
-31.17M
Net profit margin
-
-
-
-
Earnings per share
-
-
-0.62
-0.39
Interest and investment income
42.00K
1.00M
3.07M
4.06M
Interest expense
-
-
-
-
Net interest expenses
42.00K
1.00M
3.07M
4.06M
Depreciation and amortization charges
-
-
-
-
EBITDA
-3.15M
-27.38M
-30.81M
-34.99M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps